Oric Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 80 to 83 Wednesday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating tracks share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the market's biggest winners typically have an 80 or better RS Rating as they launch their biggest price moves.
Oric Pharmaceuticals Stock A Buy?
Oric Pharmaceuticals stock is trying to complete a cup with handle with an 11.27 buy point. See if the biotech stock can break out in heavy trade.
Oric Pharmaceuticals showed 0% EPS growth in the latest quarterly report, while sales growth came in at 0%.
The biotech stock holds the No. 232 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
YOU MAY ALSO LKE:
MarketSurge's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
